Related Experiment Videos
Naloxone does not interfere with the dopamine-induced decrease in gonadotropin secretion in women with polycystic
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme
|January 1, 1985
Summary
Dopamine infusion lowered luteinizing hormone (LH), follicle-stimulating hormone (FSH), and prolactin (PRL) in women with polycystic ovarian disease (PCOD). Opiate pathways were not involved in this dopamine-induced effect.
Area of Science:
- Reproductive Endocrinology
- Neuroendocrinology
Background:
- Polycystic ovarian disease (PCOD) is often associated with hormonal imbalances, including elevated luteinizing hormone (LH).
- Dopaminergic pathways are known to play a role in regulating pituitary hormone secretion.
Purpose of the Study:
- To investigate the effect of dopamine infusion on serum LH, FSH, and PRL levels in women with PCOD.
- To determine the involvement of opiatergic pathways in the dopaminergic regulation of these hormones in PCOD.
Main Methods:
- Six women with laparoscopically confirmed PCOD received a dopamine infusion (4 µg/kg/min for 4 hours).
- Naloxone, an opiate antagonist, was administered (4 mg IV bolus plus 4 mg/h for 2 hours) to assess its interaction with dopamine's effects.
- Serum LH, FSH, and PRL levels were measured before and after treatments.
Main Results:
- Dopamine infusion significantly decreased serum LH, FSH, and PRL levels, indicating reduced dopaminergic activity in these subjects.
- The addition of naloxone did not alter the inhibitory effect of dopamine on LH, FSH, and PRL secretion.
- This suggests that opiatergic pathways are not directly implicated in the dopamine-induced suppression of LH secretion in PCOD.
Conclusions:
- Dopamine exerts an inhibitory influence on LH, FSH, and PRL secretion in women with PCOD.
- The findings suggest that opiatergic pathways do not directly mediate the suppressive effects of dopamine on LH secretion in LH-dependent PCOD.